Smith & Nephew plc (LON:SN - Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 1,041.71 ($13.98) and traded as high as GBX 1,088.50 ($14.61). Smith & Nephew shares last traded at GBX 1,077.50 ($14.47), with a volume of 1,325,064 shares changing hands.
Smith & Nephew Price Performance
The company has a debt-to-equity ratio of 70.22, a current ratio of 2.51 and a quick ratio of 0.84. The company's 50 day moving average price is GBX 1,056.31 and its 200 day moving average price is GBX 1,043.44. The firm has a market capitalization of £11.83 billion, a P/E ratio of 38.87, a PEG ratio of 0.46 and a beta of 0.62.
Insider Activity
In other Smith & Nephew news, insider Jeremy (Jez) Maiden acquired 1,855 shares of Smith & Nephew stock in a transaction on Thursday, May 1st. The shares were purchased at an average cost of GBX 1,070 ($14.36) per share, with a total value of £19,848.50 ($26,645.86). Also, insider Sybella Stanley acquired 3,810 shares of Smith & Nephew stock in a transaction on Wednesday, March 26th. The stock was acquired at an average cost of GBX 1,101 ($14.78) per share, for a total transaction of £41,948.10 ($56,313.73). 0.19% of the stock is owned by insiders.
Smith & Nephew Company Profile
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Further Reading
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
